New drug combo shows promise in early brain cancer trial
NCT ID NCT06095375
First seen Jan 11, 2026 · Last updated Jun 11, 2026 · Updated 33 times
Summary
This early-phase study tested adding the drug regorafenib to standard chemotherapy (temozolomide) with or without radiation for people newly diagnosed with a specific type of aggressive brain cancer (MGMT-methylated glioblastoma). The main goal was to find the safest dose and check for side effects. 21 adults took part, and researchers monitored how well they tolerated the treatment and how the cancer responded.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA, IDH-WILDTYPE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Humanitas Research Hospital
Rozzano, 20089, Italy
-
Istituto Oncologico Veneto IRCCS
Padova, 35128, Italy
Conditions
Explore the condition pages connected to this study.